NCT04564898 2026-01-08TriComBGruppo Oncologico del Nord-OvestPhase 1/2 Active not recruiting48 enrolled
NCT07012954 2025-06-24ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRCSun Yat-sen UniversityPhase 1/2 Recruiting64 enrolled
NCT04940546 2024-12-03Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM PatientsSun Yat-sen UniversityPhase 1/2 Active not recruiting36 enrolled
NCT03439462 2024-01-02Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal CancerAadi Bioscience, Inc.Phase 1/2 Completed60 enrolled 14 charts